VKTX 8-K
Viking Therapeutics, Inc. (VKTX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
In this report, “Viking Therapeutics,” “Viking,” “Company,” “we,” “us” and “our” refer to Viking Therapeutics, Inc.
Item 2.02 Results of Operations and Financial Condition.
On July 23, 2025, we issued a press release reporting our financial results for the second quarter ended June 30, 2025 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No |
|
Description |
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded with the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Viking Therapeutics, Inc. |
|
|
|
|
Date: |
July 23, 2025 |
By: |
/s/ Brian Lian, Ph.D. |
|
|
|
Brian Lian, Ph.D. |
Exhibit 99.1
Conference call scheduled for 4:30 p.m. ET today
SAN DIEGO, July 23, 2025 -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developments.
Highlights from the Quarter Ended June 30, 2025, and Other Recent Events:
“The Viking team achieved significant execution and clinical milestones during the first half of 2025,” stated Brian Lian, Ph.D., chief executive officer of Viking. “With respect to our VK2735 program for obesity, we recently announced the initiation of the VANQUISH Phase 3 registration program, consisting of two studies: one in patients with obesity and one in patients with obesity and type 2 diabetes. Also during the first half of the year, we announced both the initiation and completion of enrollment in the Phase 2 VENTURE-Oral Dosing study of our oral tablet formulation of VK2735. We believe the study’s rapid enrollment speaks to continued strong demand for new and differentiated weight loss therapies. We remain on track to announce top-line data from the VENTURE-Oral study in the second half of the year. With respect to our amylin agonist program, we continue to make progress toward an IND filing, which we expect to submit later this year. Importantly, we completed the second quarter with a strong balance sheet providing the runway to support the advancement of VK2735 through Phase 3 clinical trials, in addition to supporting further progress with other key development programs.”
Pipeline and Recent Corporate Highlights
In 2024, Viking announced positive top-line results from its Phase 2 VENTURE study of subcutaneous VK2735 in obesity. The VENTURE trial successfully achieved its primary and secondary endpoints, with subjects receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. After 13 weekly doses, subjects receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7%. VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with the majority of observed adverse events (AEs) being reported as mild or moderate. Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo. The results of the VENTURE study were presented in November 2024 at ObesityWeek, the annual meeting of The Obesity Society.
Based on these promising Phase 2 results, along with feedback from a Type C meeting and subsequent End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the company advanced VK2735 into Phase 3 development for obesity. In the second quarter, the company announced the initiation of the VANQUISH Phase 3 clinical program, which includes two studies evaluating VK2735: one in adults with obesity and one in adults with obesity or who are overweight and have type 2 diabetes. Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks. The VANQUISH-1 study will target enrollment of approximately 4,500 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study will target enrollment of approximately 1,100 adults with type 2 diabetes with obesity or who are overweight. Participants in both trials will be randomized to one of four weekly treatment arms of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.
The primary endpoint of the trials is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures, including the percentage of patients who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction. Each study will include an open-label extension allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period.
Viking will provide further updates on the VANQUISH program as these studies progress.
In 2024, Viking reported the results from a Phase 1 multiple ascending dose trial evaluating oral VK2735 doses ranging from 2.5 mg to 100 mg. This trial successfully achieved its primary and secondary objectives, with the results showing that cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2% after 28 days. Persistent weight loss effects ranging up to 8.3% from baseline were observed at follow-up visits through Day 57, four weeks after the last dose of VK2735 was administered. Oral VK2735 also demonstrated encouraging safety and tolerability through 28 days of once-daily dosing at doses up to and including 100 mg. The majority of observed treatment emergent adverse events were mild or moderate, with the majority reported as mild. These results were presented last November at ObesityWeek 2024.
In January 2025, the company announced the initiation of the Phase 2 VENTURE-Oral Dosing trial in subjects with obesity. This trial is a randomized, double-blind, placebo-controlled multicenter study designed to evaluate the safety, tolerability, pharmacokinetics and weight loss efficacy of VK2735 dosed as an oral tablet once daily for 13 weeks. The target population consists of adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. Enrolled subjects are evenly randomized to one of six dosing arms or placebo. The primary endpoint of the study is the percent change in body weight from baseline after 13 weeks of treatment. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures.
In March, Viking announced completion of enrollment for this trial, enrolling approximately 280 patients. The company expects to report the results from this study in the second half of 2025.
In 2024 Viking announced a new, internally developed DACRA program for the treatment of obesity. In vivo data from this program were presented at the 2024 American Diabetes Association’s (ADA’s) Annual Scientific Sessions. The company’s ADA presentation highlighted the effects of treatment on body weight, food intake and metabolic profile in both healthy rats and in diet-induced obese mice. The results demonstrated that Viking's DACRAs reduced food intake in rodents following a single subcutaneous dose.
Viking plans to file an investigational new drug (IND) application for this program in the fourth quarter of 2025.
BTIG Virtual Biotechnology Conference 2025
Virtual
July 29 – 30, 2025
Cantor Global Healthcare Conference
New York, NY
September 3 – 5, 2025
Morgan Stanley 23rd Annual Global Healthcare Conference
New York, NY
September 8 - 10, 2025
Bernstein’s 2nd Annual Healthcare Forum
New York, NY
September 23 - 25, 2025
Stifel 2025 Virtual Cardiometabolic Forum
Virtual
September 30, 2025
Second Quarter and Six Months 2025 Financial Highlights
Second Quarter ended June 30, 2025 and 2024
Research and development expenses were $60.2 million for the three months ended June 30, 2025, compared to $23.8 million for the same period in 2024. The increase was primarily due to increased expenses related to clinical studies, manufacturing for the company’s drug candidates, pre-clinical studies, stock-based compensation and salaries and benefits.
General and administrative expenses were $14.4 million for the three months ended June 30, 2025, compared to $10.3 million for the same period in 2024. The increase was primarily due to increased expenses related to stock-based compensation and salaries and benefits, partially offset by decreased expenses related to legal and patent services.
For the three months ended June 30, 2025, Viking reported a net loss of $65.6 million, or $0.58 per share, compared to a net loss of $22.3 million, or $0.20 per share, in the corresponding period in 2024. The increase in net loss for the three months ended June 30, 2025, was primarily due to the increase in research and development expenses and general and administrative expenses, noted previously, compared to the same period in 2024.
Six Months Ended June 30, 2025 and 2024
Research and development expenses were $101.5 million for the six months ended June 30, 2025, compared to $47.9 million for the same period in 2024. The increase was primarily due to increased expenses related to clinical studies, manufacturing for the company’s drug candidates, stock-based compensation and salaries and benefits, partially offset by decreased expenses related to pre-clinical studies.
General and administrative expenses were $28.5 million for the six months ended June 30, 2025, compared to $20.3 million for the same period in 2024. The increase was primarily due to increased expenses related to stock-based compensation, legal and patent services and insurance, partially offset by decreased expenses related to third party consultants.
For the six months ended June 30, 2025, Viking reported a net loss of $111.2 million, or $0.99 per share, compared to a net loss of $49.6 million, or $0.46 per share, in the corresponding period in 2024. The increase in net loss for the six months ended June 30, 2025, was primarily due to the increase in research and development expenses and general and administrative expenses, noted previously, partially offset by increased interest income, compared to the same period in 2024.
Balance Sheet as of June 30, 2025
At June 30, 2025, Viking held cash, cash equivalents and short-term investments of $808 million, compared to $903 million as of December 31, 2024.
Conference Call
Management will host a conference call to discuss Viking’s second quarter 2025 financial results today at 4:30 pm Eastern. To participate in the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until July 30, 2025, by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering conference ID # 4078954. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking’s website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of Viking’s website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed
Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company’s newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 demonstrated a promising safety profile and was well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and the company's other incretin and other receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements except as required by law.
Viking Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Revenues |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
60,153 |
|
|
|
23,769 |
|
|
|
101,543 |
|
|
|
47,872 |
|
General and administrative |
|
|
14,421 |
|
|
|
10,285 |
|
|
|
28,500 |
|
|
|
20,255 |
|
Total operating expenses |
|
|
74,574 |
|
|
|
34,054 |
|
|
|
130,043 |
|
|
|
68,127 |
|
Loss from operations |
|
|
(74,574 |
) |
|
|
(34,054 |
) |
|
|
(130,043 |
) |
|
|
(68,127 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Amortization of financing costs |
|
|
(24 |
) |
|
|
(18 |
) |
|
|
(48 |
) |
|
|
(46 |
) |
Interest income, net |
|
|
9,033 |
|
|
|
11,820 |
|
|
|
18,897 |
|
|
|
18,565 |
|
Realized gain on investments, net |
|
|
4 |
|
|
|
2 |
|
|
|
4 |
|
|
|
2 |
|
Total other income, net |
|
|
9,013 |
|
|
|
11,804 |
|
|
|
18,853 |
|
|
|
18,521 |
|
Net loss |
|
|
(65,561 |
) |
|
|
(22,250 |
) |
|
|
(111,190 |
) |
|
|
(49,606 |
) |
Other comprehensive loss, net of tax: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized gain (loss) on securities |
|
|
26 |
|
|
|
(699 |
) |
|
|
589 |
|
|
|
(1,824 |
) |
Foreign currency translation gain (loss) |
|
|
24 |
|
|
|
26 |
|
|
|
33 |
|
|
|
(59 |
) |
Comprehensive loss |
|
$ |
(65,511 |
) |
|
$ |
(22,923 |
) |
|
$ |
(110,568 |
) |
|
$ |
(51,489 |
) |
Basic and diluted net loss per share |
|
$ |
(0.58 |
) |
|
$ |
(0.20 |
) |
|
$ |
(0.99 |
) |
|
$ |
(0.46 |
) |
Weighted-average shares used to compute basic |
|
|
112,134 |
|
|
|
110,390 |
|
|
|
112,102 |
|
|
|
106,924 |
|
Viking Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
|
|
June 30, |
|
|
December 31, |
|
||
|
|
(Unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
33,880 |
|
|
$ |
26,676 |
|
Short-term investments – available-for-sale |
|
|
773,844 |
|
|
|
875,936 |
|
Prepaid clinical trial and preclinical study costs |
|
|
16,478 |
|
|
|
3,476 |
|
Prepaid expenses and other current assets |
|
|
2,815 |
|
|
|
1,128 |
|
Total current assets |
|
|
827,017 |
|
|
|
907,216 |
|
Right-of-use assets |
|
|
780 |
|
|
|
1,003 |
|
Deferred financing costs |
|
|
8 |
|
|
|
56 |
|
Deposits |
|
|
46 |
|
|
|
46 |
|
Total assets |
|
$ |
827,851 |
|
|
$ |
908,321 |
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
5,494 |
|
|
$ |
9,813 |
|
Other accrued liabilities |
|
|
26,018 |
|
|
|
17,111 |
|
Lease liability, current |
|
|
468 |
|
|
|
489 |
|
Total current liabilities |
|
|
31,980 |
|
|
|
27,413 |
|
Lease liability, net of current portion |
|
|
410 |
|
|
|
630 |
|
Total long-term liabilities |
|
|
410 |
|
|
|
630 |
|
Total liabilities |
|
|
32,390 |
|
|
|
28,043 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ equity: |
|
|
|
|
|
|
||
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024 |
|
|
— |
|
|
|
— |
|
Common stock, $0.00001 par value: 300,000,000 shares authorized at June 30, 2025 and December 31, 2024; 112,329,709 shares issued and outstanding at June 30, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024 |
|
|
1 |
|
|
|
1 |
|
Treasury stock at cost, no shares at June 30, 2025 and December 31, 2024 |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
1,394,723 |
|
|
|
1,368,972 |
|
Accumulated deficit |
|
|
(599,097 |
) |
|
|
(487,907 |
) |
Accumulated other comprehensive loss |
|
|
(166 |
) |
|
|
(788 |
) |
Total stockholders’ equity |
|
|
795,461 |
|
|
|
880,278 |
|
Total liabilities and stockholders’ equity |
|
$ |
827,851 |
|
|
$ |
908,321 |
|
Contacts:
Viking Therapeutics
Greg Zante
Chief Financial Officer
858-704-4672
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
Tim Brons (Media)
415-675-7402